leadf
logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical files provisional Australian patent application for blue scorpion venom-based brain cancer treatment

The application, titled, "Cyclic Peptides and Uses Thereof,” is meant to protect the lead peptides identified in the company’s blue scorpion venom research

Blue scorpion
Peptides derived from BSV have shown promise in delineating glioma tissue and preventing the invasion of gliomas through inhibition of extracellular matrix metalloprotease

PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) (FRA:18H) filed a provisional application at the Australian Patent Office on December 22 to seek protection for certain cyclic peptides and their use in prevention and treatment of brain cancer, the company announced Tuesday. 

The application, titled, 'Cyclic Peptides and Uses Thereof,' is meant to protect the lead peptides identified in the company’s blue scorpion venom (BSV) research that appear to show the most potential for the treatment of glioblastoma multiforme (GBM), a type of cancer that begins in the brain. 

Peptides derived from BSV have shown promise in delineating glioma (brain cancer) tissue and preventing the invasion of gliomas through inhibition of extracellular matrix metalloprotease (MMP), the company said. 

READ: PreveCeutical announces successful lab development of a cannabinoid Sol-Gel formulation to prevent or treat coronavirus

"We are very excited with the results of the BSV program, and in particular with this lead peptide. Our plan is to utilize these results for a number of treatments, including management of GBM,” CEO Stephen Van Deventer said in a statement.

With the completion of three of its research programs, PreveCeutical is actively working on the development, clinical trials and commercialization of its products. The company has filed a number of provisional patent applications to protect the intellectual property from its research programs.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: PreveCeutical Medical Inc.

Price: 0.03 CAD

CSE:PREV
Market: CSE
Market Cap: $14.76 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

PreveCeutical Medical announces completion on analgesic program is near

PreveCeutical Medical (CSE:PREV-OTCQB: PRVCF) CEO Stephen Van Deventer joined Steve Darling from Proactive Vancouver with news the company’s current stage of research for its disulfide linker technology will be completed soon. Van Deventer telling Proactive about the program and what the next...

on 23/7/20

2 min read